Table 2 Details of vaccination histories of study participants recovered from SARS-CoV-2 BA.5 infection, Chengdu China, December 2022– January 2023 (n = 108)
From: Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection
Volunteer | Sex | Age | The first dose | The second dose | The third dose | Group |
|---|---|---|---|---|---|---|
1 | Male | 34 | / | / | / | Unvaccinated group (n = 22): 22 adult participants have not received injection of vaccine with infection |
2 | Female | 30 | / | / | / | |
3 | Female | 30 | / | / | / | |
4 | Female | 25 | / | / | / | |
5 | Female | 32 | / | / | / | |
6 | Male | 30 | / | / | / | |
7 | Female | 31 | / | / | / | |
8 | Female | 28 | / | / | / | |
9 | Female | 31 | / | / | / | |
10 | Female | 33 | / | / | / | |
11 | Female | 32 | / | / | / | |
12 | Male | 29 | / | / | / | |
13 | Male | 24 | / | / | / | |
14 | Female | 27 | / | / | / | |
15 | Male | 24 | / | / | / | |
16 | Female | 31 | / | / | / | |
17 | Male | 31 | / | / | / | |
18 | Male | 33 | / | / | / | |
19 | Female | 35 | / | / | / | |
20 | Female | 37 | / | / | / | |
21 | Male | 35 | / | / | / | |
22 | Female | 41 | / | / | / | |
23 | Male | 27 | CoronaVac | CoronaVac | / | 2 doses of IV group (n = 25): adult participants who have received two doses of inactivated vaccines with infection |
24 | Female | 28 | CoronaVac | CoronaVac | / | |
25 | Male | 25 | CoronaVac | CoronaVac | / | |
26 | Female | 24 | CoronaVac | CoronaVac | / | |
27 | Male | 31 | CoronaVac | CoronaVac | / | |
28 | Male | 21 | BBIBP | BBIBP | / | |
29 | Female | 25 | CoronaVac | CoronaVac | / | |
30 | Female | 25 | BBIBP | BBIBP | / | |
31 | Male | 25 | CoronaVac | CoronaVac | / | |
32 | Female | 25 | BBIBP | BBIBP | / | |
33 | Female | 31 | CoronaVac | CoronaVac | / | |
34 | Male | 24 | CoronaVac | CoronaVac | / | |
35 | Male | 27 | CoronaVac | CoronaVac | / | |
36 | Female | 24 | CoronaVac | CoronaVac | / | |
37 | Male | 31 | CoronaVac | BBIBP | / | |
38 | Male | 31 | BBIBP | BBIBP | / | |
39 | Female | 33 | BBIBP | BBIBP | / | |
40 | Male | 35 | CoronaVac | BBIBP | / | |
41 | Female | 37 | CoronaVac | BBIBP | / | |
42 | Male | 35 | CoronaVac | CoronaVac | / | |
43 | Male | 41 | CoronaVac | CoronaVac | / | |
44 | Female | 43 | CoronaVac | CoronaVac | / | |
45 | Female | 31 | CoronaVac | CoronaVac | / | |
46 | Male | 47 | CoronaVac | CoronaVac | / | |
47 | Female | 49 | CoronaVac | CoronaVac | / | |
48 | Female | 23 | CoronaVac | CoronaVac | CoronaVac | 3 doses of IV group (n = 39): adult participants who have received three doses of inactivated vaccines with infection |
49 | Female | 22 | CoronaVac | CoronaVac | CoronaVac | |
50 | Male | 29 | CoronaVac | CoronaVac | CoronaVac | |
51 | Female | 23 | CoronaVac | CoronaVac | CoronaVac | |
52 | Male | 25 | CoronaVac | CoronaVac | CoronaVac | |
53 | Male | 29 | BBIBP | BBIBP | BBIBP | |
54 | Female | 52 | CoronaVac | CoronaVac | CoronaVac | |
55 | Female | 29 | BBIBP | BBIBP | BBIBP | |
56 | Female | 28 | CoronaVac | CoronaVac | CoronaVac | |
57 | Female | 25 | CoronaVac | CoronaVac | CoronaVac | |
58 | Female | 24 | CoronaVac | CoronaVac | CoronaVac | |
59 | Female | 24 | CoronaVac | BBIBP | BBIBP | |
60 | Female | 24 | CoronaVac | BBIBP | BBIBP | |
61 | Female | 23 | CoronaVac | CoronaVac | CoronaVac | |
62 | Female | 35 | CoronaVac | CoronaVac | CoronaVac | |
63 | Female | 30 | CoronaVac | CoronaVac | BBIBP | |
64 | Female | 23 | CoronaVac | CoronaVac | CoronaVac | |
65 | Male | 28 | CoronaVac | BBIBP | BBIBP | |
66 | Female | 31 | CoronaVac | CoronaVac | CoronaVac | |
67 | Female | 28 | CoronaVac | CoronaVac | CoronaVac | |
68 | Female | 41 | CoronaVac | CoronaVac | CoronaVac | |
69 | Female | 27 | CoronaVac | CoronaVac | CoronaVac | |
70 | Male | 35 | CoronaVac | CoronaVac | CoronaVac | |
71 | Male | 42 | CoronaVac | CoronaVac | CoronaVac | |
72 | Female | 25 | CoronaVac | CoronaVac | CoronaVac | |
73 | Female | 41 | CoronaVac | CoronaVac | CoronaVac | |
74 | Female | 27 | CoronaVac | CoronaVac | CoronaVac | |
75 | Female | 36 | CoronaVac | CoronaVac | CoronaVac | |
76 | Male | 39 | BBIBP | BBIBP | BBIBP | |
77 | Male | 28 | CoronaVac | CoronaVac | CoronaVac | |
78 | Female | 31 | CoronaVac | CoronaVac | CoronaVac | |
79 | Male | 28 | CoronaVac | CoronaVac | CoronaVac | |
80 | Female | 41 | BBIBP | BBIBP | BBIBP | |
81 | Male | 27 | BBIBP | BBIBP | BBIBP | |
82 | Male | 35 | CoronaVac | BBIBP | BBIBP | |
83 | Female | 42 | CoronaVac | BBIBP | BBIBP | |
84 | Female | 25 | CoronaVac | BBIBP | BBIBP | |
85 | Male | 41 | BBIBP | BBIBP | BBIBP | |
86 | Female | 27 | CoronaVac | CoronaVac | CoronaVac | |
87 | Male | 73 | BBIBP | BBIBP | BBIBP | Elderly group (n = 22): elderly participants who were over 65 years with infection |
88 | Female | 71 | CoronaVac | CoronaVac | CoronaVac | |
89 | Male | 66 | CoronaVac | CoronaVac | CoronaVac | |
90 | Male | 66 | CoronaVac | CoronaVac | CoronaVac | |
91 | Male | 69 | CoronaVac | CoronaVac | CoronaVac | |
92 | Male | 79 | CoronaVac | CoronaVac | CoronaVac | |
93 | Male | 83 | CoronaVac | CoronaVac | CoronaVac | |
94 | Female | 69 | CoronaVac | CoronaVac | CoronaVac | |
95 | Female | 73 | CoronaVac | CoronaVac | CoronaVac | |
96 | Male | 71 | CoronaVac | CoronaVac | CoronaVac | |
97 | Male | 72 | CoronaVac | CoronaVac | CoronaVac | |
98 | Female | 70 | CoronaVac | CoronaVac | CoronaVac | |
99 | Male | 73 | CoronaVac | CoronaVac | CoronaVac | |
100 | Female | 71 | CoronaVac | CoronaVac | CoronaVac | |
101 | Male | 66 | CoronaVac | CoronaVac | CoronaVac | |
102 | Female | 66 | CoronaVac | CoronaVac | CoronaVac | |
103 | Male | 69 | CoronaVac | CoronaVac | CoronaVac | |
104 | Male | 79 | CoronaVac | CoronaVac | CoronaVac | |
105 | Female | 83 | CoronaVac | CoronaVac | CoronaVac | |
106 | Female | 69 | CoronaVac | CoronaVac | CoronaVac | |
107 | Male | 73 | CoronaVac | CoronaVac | CoronaVac | |
108 | Female | 71 | CoronaVac | CoronaVac | CoronaVac |
